首页> 外文期刊>BMC Musculoskeletal Disorders >Clinical effect modifiers of antibiotic treatment in patients with chronic low back pain and Modic changes - secondary analyses of a randomised, placebo-controlled trial (the AIM study)
【24h】

Clinical effect modifiers of antibiotic treatment in patients with chronic low back pain and Modic changes - secondary analyses of a randomised, placebo-controlled trial (the AIM study)

机译:慢性低腰疼痛患者抗生素治疗的临床疗效改性剂及致力变化 - 随机,安慰剂对照试验的二次分析(AIM研究)

获取原文
           

摘要

Randomised trials on antibiotic treatment for patients with chronic low back pain and vertebral endplate changes visible on MRI (Modic changes) have shown mixed results. A possible explanation might be a real treatment effect in subgroups of the study populations. The purpose of the present study was to explore potential clinical effect modifiers of 3-months oral amoxicillin treatment in patients with chronic low back pain and type I or II Modic changes at the level of a previous lumbar disc herniation. We performed analyses of effect modifiers on data from AIM, a double-blind parallel-group multicentre trial. One hundred eighty patients with chronic low back pain, previous disc herniation, Modic change type I (n?=?118) or type II (n?=?62) were randomised to 3-months oral treatment with 750?mg amoxicillin (n?=?89) or placebo (n?=?91) three times daily. The primary outcome was the Roland-Morris Disability Questionnaire (RMDQ) score (possible values 0–24) at 1-year follow-up in the intention-to-treat population. The predefined minimal clinically important between-group mean difference was 4 RMDQ points (not reached in the primary analysis of AIM). Predefined baseline characteristics were analysed as potential effect modifiers, four primary (type I Modic changes, previous disc surgery, positive pain provocation test, high CRP) and five exploratory (disturbed sleep, constant low back pain, short duration of low back pain, younger age, and male) using ANCOVA with interaction terms. None of the four primary potential effect modifiers had strong evidence of modifying the treatment effect. In patients younger than 40?years the difference in mean RMDQ score between the treatment groups was ??4.0 (95%CI, ??6.9 to ??1.2), compared to ??0.5 (95%CI, ??2.3 to 1.3) in patients 40?years or older, both in favour of amoxicillin treatment (exploratory analysis). We did not find evidence for convincing clinical effect modifiers of antibiotic treatment in patients with chronic low back pain and Modic changes. Our results for younger age in these explorative analyses should not affect clinical treatment decisions without confirmation in future studies. ClinicalTrials.gov NCT02323412 , First registered 23 December 2014.
机译:随机试验对慢性低腰疼痛患者的抗生素治疗和MRI可见的椎体底板变化(修饰变化)显示了混合结果。可能的解释可能是研究人群的亚组中的真正治疗效果。本研究的目的是探讨慢性低腰疼痛患者3个月口服阿莫西林治疗的潜在临床疗效改性剂,患者患者患者,I型或II型态度变化在先前的腰椎间盘突出水平。我们在目标中对数据进行了影响的分析,一个双盲并联集团的多环境试验。慢性低腰疼痛的一百八患者,先前的椎间盘突出症,态度变化型I(n?=α118)或II型(N?=β62)被随机化为750毫莫西霉素(n ?=?89)或安慰剂每天三次(n?=?91)。主要结果是罗兰 - 莫里斯残疾问卷(RMDQ)评分(RMDQ)评分(RMDQ)评分(RMDQ)评分(RMDQ)分数(可能的价值0-24)在意向对治疗人口的后续行动中。组平均差异之间的预定义最小临床重要性是4个RMDQ点(在瞄准的主要分析中未达到)。预定义的基线特征被分析为潜在的效果改性剂,四次初级(I型修饰变化,先前光盘手术,阳性疼痛挑衅测试,高CRP)和五个探索性(睡眠不变,持续低腰部疼痛,腰痛短疼痛短疼痛,年轻年龄和男性)使用互动条款的Ancova。四个主要潜在效应改性剂中的任何一个都具有强烈的证据来修改治疗效果。在40岁的患者中,治疗组之间的平均RMDQ评分的差异为4.0(95%CI,6.9至约2),相比?0.5(95%CI,?? 2.3至1.3 )在40岁的患者中,岁月或以上,都赞成阿莫西林治疗(探索性分析)。我们没有发现慢性低腰疼痛患者抗生素治疗的临床效果改性剂的证据表明。我们在这些探索性分析中的年轻年龄的结果不应影响未来研究的未确认的临床治疗决策。 ClinicalTrials.gov NCT02323412,2014年12月23日第一次注册。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号